Prolactin activates Stat1 but does not antagonize Stat1 activation and growth inhibition by type I interferons in human breast cancer cells

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1914-1919

  Schaber, John D ^a   Fang, Hui ^a   Xu, Jun ^a   Grimley, Philip M ^a   Rui, Hallgeir ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; PROLACTIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOBLOTTING; INTERFERON TYPE I; PHOSPHORYLATION; PROLACTIN; RABBITS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0032080788     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Einhorn, S., and Strander, H. Interferon treatment of human malignancies. Med. Oncol. Tumor Pharmacother., 10: 25-29, 1993.
2. Hansen, R. M., and Borden, E. C. Current status of interferons in the treatment of cancer. Oncology (Basel), 11: 19-24, 1992.
3. Friedman, R. M. Antitumor effects of interferons. J. Exp. Pathol., 3: 203-222, 1987.
4. Seymour, L., and Bezwoda, W. R. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biological effects of two growth modulators. Br. J. Cancer, 68: 352-356, 1993.
5. Macheledt, J. E., Buzdar, A. U., Hortobagyi, G. N., Frye, D. K., Gutterman, J. U., and Holmes, F. A. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res. Treat., 18: 165-170, 1991.
6. Einhorn, S., and Grander, D. Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res., 16: 275-281, 1996.
7. Darnell, J. E. Stats and gene regulation. Science (Washington DC), 277: 1630-1635, 1997.
8. Darnell, J. E. The Jak-Stat pathway: summary of initial studies and recent advances. Recent Prog. Horm. Res., 51: 391-403, 1996.
9. Ihle, J. N., and Kerr, I. M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet., 11: 69-74, 1995.
10. Schindler, C., and Darnell, J. E. Transcriptional responses to polypeptide ligands: the Jak-Stat pathway. Annu. Rev. Biochem., 64: 621-651, 1995.
11. Darnell, J. E., Kerr, I. M., and Stark, G. R. Jak-Stat pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Washington DC), 264: 1415-1421, 1994.
12. Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., and Silvennoinen, O. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol., 13: 369-398, 1995.
13. Finbloom, D. S., and Larner, A. C. Regulation of the Jak-Stat signaling pathway. Cell. Signalling, 7: 739-745, 1995.
14. O'Shea, J. J. Jaks, Stats, cytokine signal transduction, and immunoregulation: are we there yet? Immunity, 7: 1-11, 1997.
15. Bluyssen, H. A., Muzaffar, R., Vlieststra, R. J., van der Made, A. C., Leung, S., Stark, G. R., Kerr, I. M., Trapman, J., and Levy, D. E. Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc. Natl. Acad. Sci. USA, 92: 5645-5649, 1995.
16. Li, X., Leung, S., Qureshi, S., Darnell, J. E., and Stark, G. R. Formation of Stat1-Stat2 heterodimers and their role in the activation of IRF-1 gene transcription by α-interferon. J. Biol. Chem., 271: 5790-5794, 1996.
17. Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y., and Fu, X. Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by Stat1. Science (Washington DC), 272: 719-722, 1996.
18. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., and Darnell, J. E., Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc. Natl. Acad. Sci. USA, 93: 7673-7678, 1996.
19. Beadling, C., Gushin, D., Witthuhn, B. A., Ziemiecki, A., Ihle, J. N., Kerr, I. M., and Cantrell, D. A. Activation of Jak kinases and Stat proteins by interleukin-2 and α interferon, but not the T-cell antigen receptor, in human T lymphocytes. EMBO J., 13: 5605-5615, 1994.
20. Ghislain, J. J., and Fish, E. N. Application of genomic DNA affinity chromatography identifies multiple interferon-α-regulated Stat2 complexes. J. Biol. Chem., 271: 12408-12413, 1996.
21. Kirken, R. A., Malabarba, M. G., Xu, J., Liu, X., Farrar, W. L., Hennighausen, L., Larner, A. C., Grimley, P. M., and Rui, H. Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J. Biol. Chem., 272: 14098-15003, 1997.
22. DaSilva, L., Rui, H., Erwin, R. A., Howard, O. M. Z., Kirken, R. A., Malabarba, M. G., Hackett, R. H., Larner, A. C., and Farrar, W. L. Prolactin recruits Stat1, Stat3, Stat5 independent of conserved receptor tyrosines Tyr402, Tyr479, Tyr515, and Tyr580. Mol. Cell. Endocrinol., 117: 131-140, 1996.
23. Bonneterre, J., Peyrat, J. P., Beuscart, R., and Demaille, A. Biological and clinical aspects of prolactin receptors in human breast cancer. J. Steroid Biochem. Mol. Biol., 37: 977-981, 1990.
24. Murphy, J. L., Murphy, L. C., Vrhovesek, E., Sutherland, R. L., and Lazarus, L. Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. Cancer Res., 44: 1963-1968, 1984.
25. Ginsburg, E., and Vonderhaar, B. K. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res., 55: 2591-2595, 1995.
26. Clevenger, C. V., Chang, W. P., Ngo, W., Pasha, T. L., Montone, K. T., and Tomaszewski, J. E. Expression of prolactin and prolactin receptor in human breast carcinoma: evidence for an autocrine/paracrine loop. Am. J. Pathol., 146: 695-705, 1995.
27. Somers, W., Ultsch, M., De Vos, A. M., and Kossiakoff, A. A. The X-ray structure of a growth hormone-prolactin receptor complex. Nature (Lond.), 372: 478-481, 1994.
28. van der Pompe, G., Antoni, M. H., and Heijnen, C. J. Elevated levels and attenuated ACTH and Cortisol responses to behavioral challenge in women with metastatic breast cancer. Psychoneuroendocrinology, 21: 361-374, 1996.
29. Fleischmann, W. R., Newton, R. C., Fleischmann, C. M., Colburn, N. H., and Brysk, M. M. Discrimination between nonmalignant and malignant cells by combination of IFN-γ and IFN-α/β. J. Biol. Response Modif., 3: 397-405, 1984.
30. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 277: 680-688, 1970.
31. Wilson, K. C., and Finbloom, D. S. Interferon γ rapidly induces in human monocytes a DNA-binding factor that recognizes the γ response region within the promoter of the gene for the high-affinity Fc γ receptor. Proc. Natl. Acad. Sci. USA, 89: 11964-11968, 1992.
32. DaSilva, L., Howard, O. M., Rui, H., Kirken, R. A., and Farrar, W. L. Growth signaling and Jak2 activation mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J. Biol. Chem., 269: 18267-18270, 1994.
33. Norusis, M. J. SPSS/PC Base Manual, SPSS version 6.1. Chicago, IL: SPSS, Inc., 1994.
34. Shui, R. P. Prolactin receptors in human breast cancer cells in long-term tissue culture. Cancer Res., 39: 4381-4386, 1979.
35. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., and Darnell, J. E., Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc. Natl. Acad. Sci. USA, 93: 7673-7678, 1996.
36. Meinke, A., Barahmand-Pour, F., Wohrl, S., Stoiber, D., and Decker, T. Activation of different Stat5 isoforms contributes to cell type-restricted signaling in response to interferons. Mol. Cell. Biol., 16: 6937-6944, 1996.
37. Coradini, D., Biffi, A., Pirronello, E., and Di Fronzo, G. The effect of α-, β-, and γ-interferon on the growth of breast cancer cell lines. Anticancer Res., 14: 1779-1784, 1994.
38. Schmitt-Ney, M., Doppler, W., Ball, R. K., and Groner, B. β-Casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary gland-specific nuclear factor. Mol. Cell. Biol., 11: 3745-3755, 1991.
39. Liu, X., Robinson, G. W., Wagner, K. U., Garrett, L., Wynshaw-Boris, A., and Hennighausen, L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev., 11: 179-186, 1997.
40. D'Cunha, J., Knight, E., Jr., Haas, A. L., Truitt, R. L., and Borden, E. C. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl. Acad. Sci. USA, 93: 211-215, 1996.
41. Yu-Lee, L. Y., Hrachovy, J. A., Stevens, A. M., and Schwarz, L. A. Interferon regulatory factor 1 is an immediate-early gene under transcriptional regulation by prolactin in Nb2 T cells. Mol. Cell. Biol., 10: 3087-3094, 1990.
42. Wang, Y. F., O'Neal, K. D., and Yu-Lee, L. Y. Multiple prolactin (PRL) receptor cytoplasmic residues and Stat1 mediate PRL signaling to the interferon regulatory factor-1 promoter. Mol. Endocrinol., 11: 1353-1364, 1997.
43. Liu, X., Robinson, G. W., Gouilleux, F., Groner, B., and Hennighausen, L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl. Acad. Sci. USA, 92: 8831-8835, 1995.
44. Rui, H., Xu, J., Dong, F., Mehta, S. Fang, H., Williams, J., and Grimley, P. M. Activation of the Jak2-Stat5 signaling pathway in Nb2 lymphoma cells by an anti-apoptotic, aurintricarboxylic acid. J. Biol. Chem., 273: 28-32, 1998.
45. Kirken, R. A., Malabarba, M. G., Xu, J., Erwin, R. E., DaSilva, L., Liu, X., Hennighausen, L., Rui, H., and Farrar, W. L. Two discrete regions of interleukin-2 (IL2) receptor-β independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase. J. Biol. Chem., 272: 15459-15465, 1997.
46. Wen, Z., Zhong, Z., and Darnell, J. E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 82: 241-250, 1995.
47. David, M., Petricoin, E., Benjamin, C., Pine, R., Weber, M. J., and Larner, A. C. Requirement for MAP kinase (ERK2) activity in interferon α- and interferon β-stimulated gene expression through Stat proteins. Science (Washington DC), 269: 1721-1723, 1995.
48. Carey, G. B., and Liberti, J. P. Stimulation of receptor-associated kinase, tyrosine kinase, and MAP kinase is required for prolactin-mediated macromolecular biosynthesis and mitogenesis in Nb2 lymphoma. Arch. Biochem. Biophys., 316: 179-189, 1995.
49. Stancato, L. F., Sakatsume, M., David, M., Dent, P., Dong, F., Petricoin, E. F., Krolewski, J. J., Silvennoinen, O., Saharinen, P., Pierce, I., Marshall, C. J., Sturgill, T., Finbloom, D. S., and Larner, A. C. β-Interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a Jak1-dependent pathway. Mol. Cell. Biol., 17: 3833-3840, 1997.
50. Ihle, J. N. Stats and MAPKs: obligate or opportunistic partners in signaling. BioEssays, 18: 95-98, 1996.